KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardlytics (CDLX) EBITDA (2017 - 2025)

Cardlytics (CDLX) has disclosed EBITDA for 9 consecutive years, with -$6.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA rose 26.7% year-over-year to -$6.1 million, compared with a TTM value of -$101.8 million through Dec 2025, up 47.92%, and an annual FY2025 reading of -$101.8 million, up 47.92% over the prior year.
  • EBITDA was -$6.1 million for Q4 2025 at Cardlytics, up from -$68.9 million in the prior quarter.
  • Across five years, EBITDA topped out at $35.7 million in Q1 2022 and bottomed at -$382.6 million in Q4 2022.
  • Average EBITDA over 5 years is -$50.7 million, with a median of -$21.4 million recorded in 2021.
  • Peak annual rise in EBITDA hit 260.84% in 2022, while the deepest fall reached 2231.86% in 2022.
  • Year by year, EBITDA stood at -$16.4 million in 2021, then crashed by 2231.86% to -$382.6 million in 2022, then soared by 73.1% to -$102.9 million in 2023, then surged by 91.92% to -$8.3 million in 2024, then rose by 26.7% to -$6.1 million in 2025.
  • Business Quant data shows EBITDA for CDLX at -$6.1 million in Q4 2025, -$68.9 million in Q3 2025, and -$12.8 million in Q2 2025.